In Adacyte we are strongly commited to develop long-term relationships and mutual trust with healthcare professionals, medical societies and other organisations, to design and conduct value-added clinical trials.
Our primary concern for people living with serious chronic diseases encourages us to continually explore and investigate the full potential of both our existing and future medical technologies.
Our focus is to maximise the therapeutic value of our current and future medical devices, either in the indications already approved or addressing new unmet medical needs.
In 2020, Adacyte Therapeutics, together with JIMRO (Japan Immunoresearch Laboratories Co., Ltd), launched an ambitious clinical development program for GMA.
Over the next four years, we will conduct relevant clinical trials across Europe and US involving more than 1.000 patients, 150 investigators and 80 University Hospitals.
Contact UsFor more informationContact Us